Welcome to Paratek Medical Affairs
This web portal is intended as an educational resource for healthcare professionals practicing in the U.S. Information provided is for informational purposes and is not intended to promote the use of any product. Please review the relevant package insert for safety information and directions for use before prescribing medications.
Are you a health professional practicing in the United States?

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Publications & Presentations

Paratek is committed to enhancing public health through responsible sharing of clinical trial data.

This page contains links to publications and access to congress presentations  related to our products and may contain information regarding approved and non-approved uses, formulations, or treatment regimens. Information provided is not intended to promote any product or indication. Results reported in any single study may not reflect the overall results obtained across the product development.

Please see the Full Prescribing Information available here.

Download a complete bibliography with links to publications and presentations here.

Conference Presentations

No items found.
2021
ECCMID
accordio_arrow
ECCMID 2021
ID Week
accordio_arrow
ID Week 2021
MAD-ID
accordio_arrow
MAD-ID 2021
MHSRS
accordio_arrow
MHSRS 2021
NACCHO
accordio_arrow
NACCHO 2021
SOMSA
accordio_arrow
SOMSA 2021
TMC ANTIMICROBIAL STEWARDSHIP
accordio_arrow
TMC ANTIMICROBIAL STEWARDSHIP
World Microbe Forum
accordio_arrow
World Microbe Forum 2021
2020
ASHP
accordio_arrow
ASHP 2020
APHA-JFS
accordio_arrow
APHA-JFS 2020
ACCP
accordio_arrow
ACCP 2020
AMSUS
accordio_arrow
AMSUS 2020
ACEP
accordio_arrow
ACEP 2020
CHEST
accordio_arrow
CHEST 2020
IDWEEK
accordio_arrow
IDWEEK 2020
ECCMID
accordio_arrow
ECCMID 2020
MHSRS
accordio_arrow
MHSRS 2020
2019
SAEM
accordio_arrow
SAEM 2019
ASM Microbe
accordio_arrow
ASM Microbe 2019
ASM-ESCMID
accordio_arrow
ASM-ESCMID 2019
IDWEEK
accordio_arrow
IDWEEK 2019
ECCMID
accordio_arrow
ECCMID 2019
Activities of Omadacycline Alone and in Combination with Rifampin Against Staphylococcus aureus and Staphylococcus epidermidis in Biofilm Time Kill Analyses and a Novel In Vitro Biofilm Pharmacokinetic/Pharmacodynamic Model
Prevalence and Predictors of P. aeruginosa among Hospitalized Patients with Diabetic Foot Infections: a Multicenter Evaluation
Treatment of Wound Infection Using Omadacycline versus Linezolid: Pooled Results from Phase 3 Randomized, Double-blind, Multicenter Studies (OASIS-1 and -2)
Efficacy of Omadacycline in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Cellulitis or Abscesses
Activity of Omadacycline Against 7,000 Bacterial Isolates from the United States in the SENTRY Antimicrobial Surveillance Program (2020)
Molecular Characterization of Staphylococcus aureus Non-susceptible to Omadacycline and Susceptible to Legacy Tetracycline Agents
Omadacycline MIC Quality Control Ranges Following CLSI M23-ED5 Multiple Laboratory Design
Real-World Experience with Omadacycline for MDR/XDR Gram-Negative Infections: A Multicenter Evaluation
Effect of a Light Meal on the Pharmacodynamics of Omadacycline
Subinhibitory concentrations of omadacycline inhibit Staphylococcus aureus hemolytic activity in vitro
Proactive choice of antibiotic may reduce the risk of Clostridioides difficile infection
Updated Guidelines for Treatment and Prophylaxis of Yersinia pestis After Intentional Release
Efficacy of Omadacycline in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients with Cellulitis or Abscesses
Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
In Vitro Activity of Omadacycline against 7000 Bacterial Pathogens from the United States Stratified by Infection Type (2019)
Comparative Activity of Omadacycline Against Extended-Spectrum Beta-lactamase Positive and Negative Escherichia coli and Klebsiella pneumoniae Strains Recovered from Urine Specimens
Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and MDR/XDR Gram-Negative Infections: A Multicenter Evaluation
Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity In Vitro
Treatment of Legionella pneumophila using Omadacycline versus Moxifloxacin: Subanalysis Results from a Phase 3 Randomized Double-Blind Multicenter Study (OPTIC)
Treatment of Legionella pneumophila using Omadacycline versus Moxifloxacin: Subanalysis Results from a Phase 3 Randomized Double-Blind Multicenter Study (OPTIC)
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
Activity of Omadacycline and Comparator Agents against Bacterial Isolates from Skin, Respiratory, and Wound Infections from United States and European Medical Centers (2014 - 2019)
Treatment of Wound Infection using Omadacycline versus Linezolid: Pooled Results from Phase 3 Randomized, Double-blind, Multicenter Studies (OASIS-1 and -2)
Activity of Omadacycline and Comparator Agents Against Bacterial Pathogens from the United States by Infection Type (2019)
Self-Reported Health Status in Ambulatory Acute Bacterial Skin and Skin Structure Infection Patients Who Inject Drugs, Who Received Oral Therapy with Omadacycline or Linezolid
Epidemiology of Clostridioides Difficile Infections Among Hospitalised Community-Acquired Pneumonia Patients Who Received Empiric Treatment with Ceftriaxone Plus a Macrolide
Predicted Risk and Observed Occurrence of Clostridioides difficile Infection in Patients with Community-Acquired Bacterial Pneumonia Treated with Omadacycline or Moxifloxacin
Predicted Risk and Observed Occurrence of Clostridioides difficile Infection in Patients with Community-Acquired Bacterial Pneumonia Treated with Omadacycline or Moxifloxacin
Proactive choice of antibiotic may reduce the risk of Clostridioides difficile infection
Activity of Omadacycline and Comparator Agents Against Bacterial Pathogens from the United States by Infection Type (2019)
Epidemiology of Clostridioides Difficile Infections Among Hospitalised Community-Acquired Pneumonia Patients Who Received Empiric Treatment with Ceftriaxone Plus a Macrolide
Self-Reported Health Status in Ambulatory Acute Bacterial Skin and Skin Structure Infection Patients Who Inject Drugs, Who Received Oral Therapy with Omadacycline or Linezolid
Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline With and Without a Loading Dose
Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
In Vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections
Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
In Vitro Activity of Omadacycline against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections
Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline With and Without a Loading Dose
Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
Omadacycline is Not a Substrate for Clinically Relevant β‐Lactamase Enzymes
Bayesian Adaptive Dose‐Response Studies in Complicated and Uncomplicated Urinary Tract Infection
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
Omadacycline is Not a Substrate for Clinically Relevant β‐Lactamase Enzymes
Bayesian Adaptive Dose‐Response Studies in Complicated and Uncomplicated Urinary Tract Infection
Analysis of Pooled Microbiological Data from Two Phase 3 Studies of Omadacycline Treatment for Acute Bacterial Skin and Skin Structure Infections
Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and Gram-Negative Bacteria
In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results
Analysis of Pooled Microbiological Data from Two Phase 3 Studies of Omadacycline Treatment for Acute Bacterial Skin and Skin Structure Infections
In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results
Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria
Omadacycline Treatment of Acute Bacterial Skin and Skin Structure Infections in Intravenous Drug Users
Omadacycline Treatment of Acute Bacterial Skin and Skin Structure Infections in Intravenous Drug Users
Omadacycline Hepatic Safety: Integrated Analysis of Randomized Controlled Phase III Trials
Safety and Efficacy of Omadacycline for Treatment of Community-acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections in Patients with Mild to Moderate Renal Insufficiency
In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results
Assessment of Pharmacokinetics-Pharmacodynamics to Support Omadacycline Dosing Regimens for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Incidence of Emergency Department Visits and Hospitalizations after Outpatient Treatment with an Oral Antibiotic among Patients with Acute Bacterial Skin and Skin Structure Infections
Omadacycline Pharmacokinetics: Impact of Comorbidities
Safety and Efficacy of Omadacycline by Body Mass Index in Patients with Community-acquired Bacterial Pneumonia
Safety and Efficacy of Omadacycline for Treatment of Acute Bacterial Skin and Skin Structure Infections by Patient Body Mass Index
Omadacycline Pharmacokinetics: Impact of Comorbidities
Safety and Efficacy of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections in Patients with Mild to Moderate Renal Insufficiency
Safety and Efficacy of Omadacycline for Treatment of Acute Bacterial Skin and Skin Structure Infections by Patient Body Mass Index
Early Clinical Response and Clinical Stability as Predictors of Overall Clinical Response in Community-Acquired Bacterial Pneumonia
Early Clinical Response and Clinical Stability as Predictors of Overall Clinical Response in Community-Acquired Bacterial Pneumonia
Assessment of Pharmacokinetics-Pharmacodynamics to Support Omadacycline Dosing Regimens for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Incidence of Emergency Department Visits and Hospitalizations after Outpatient Treatment with an Oral Antibiotic among Patients with Acute Bacterial Skin and Skin Structure Infections
Omadacycline Hepatic Safety: Integrated Analysis of Randomized Controlled Phase III Trials
In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results
Cost-savings Analysis with Use of Omadacycline Among Hospitalized Community-Acquired Pneumonia Patients At Risk of Clostridium difficile Infection Being Treated with Moxifloxacin: Budget Impact Model Findings
Cost-saving Opportunities Among Hospitalized Community-Acquired Pneumonia Patients Treated with Omadacycline, an Aminomethylcycline Antibiotic with IV and Oral Formulations, Compared to Ceftriaxone and Macrolide Therapy
Improvement in Quality of Life for Adults with Acute Bacterial Skin and Skin Structure Infections Following Treatment with Omadacycline or Linezolid
Omadacycline In Vitro Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials
Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
Hospital Admission Patterns in Adult Patients with Community-acquired Bacterial Pneumonia who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
Impact of Age and Gender on Efficacy and Safety of Omadacycline versus Moxifloxacin in Community-acquired Bacterial Pneumonia
In vitro activities of omadacycline against rapidly growing mycobacteria
Omadacycline In Vitro Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the U.S. and Europe During the SENTRY Surveillance Program (2017)
Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) for Streptococcus pneumoniae (SP) and Haemophilus influenzae (HI)
In Vitro Activity of Omadacycline against Chlamydia pneumoniae
Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using A One- Compartment In Vitro Infection Model
Efficacy of Omadacycline and Linezolid against Characterized Drug Resistant S. aureus from Combined Phase 3 ABSSSI Studies
Population Pharmacokinetic (PK) Analyses of Omadacycline Using Phase 1 and Phase 3 Data
Early Clinical Response of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by PORT Risk Class: Results from the OPTIC Study
In Vitro Activity of Omadacycline Against Resistant Staphylococcus aureus
Efficacy of Omadacycline Versus Moxifloxacin in Treating Subjects From Different Geographic Regions With Community- acquired Bacterial Pneumonia (CABP)
A Phase-3 Randomized, Double-blind, Multi-centre Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects with ABSSSI (OASIS-2 Study)
Omadacycline Versus Moxifloxacin in the Treatment of Adults with Community-acquired Bacterial Pneumonia (CABP): Efficacy Analysis According to EMA Requirements
Activity of Omadacycline and Comparators against Gram-Positive and -Negative Clinical Isolates (including resistant organism subsets) Collected in 2017 from Patients in European Medical Centres: SENTRY Surveillance Programme Results
No items found.

Contact Us

In light of the COVID-19 pandemic, you may experience a busy signal when calling our Paratek Call Center. Please continue to try your call throughout the day to report adverse events and product quality complaints or obtain medical information for our products.

MSD Contact Form
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By completing this form, I verify that I requested this information completely independently and solely for my own evaluation and application to my practice, patients, or general education, or for the pharmacy and therapeutics committee. I affirm that my request was in no way prompted by Paratek Pharmaceuticals or any representative of Paratek.

Medical Information
If you would like to speak to a Paratek Medical Information Professional please call Paratek Customer Service at 1-833-PARATEK (1-833-727-2835) (Monday to Friday, 8 AM to 8 PM ET, excluding holidays) or email medinfo@paratekpharma.com
Report a Product Complaint
To report a Product Quality Complaint for a Paratek product, please call 1-833-Paratek (1-833-727-2835).
Report an Adverse Event
To report an Adverse Event for a Paratek product, please fill out a form or call us 1-833-PARATEK (1-833-727-2835). You can also contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Request follow-up from a Medical Science Director
If you would like additional information about our products or would like to discuss research ideas, please contact our MSD team.